96 related articles for article (PubMed ID: 22559004)
1. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.
Dimitrov JD; Christophe OD; Kang J; Repessé Y; Delignat S; Kaveri SV; Lacroix-Desmazes S
Biochemistry; 2012 May; 51(20):4108-16. PubMed ID: 22559004
[TBL] [Abstract][Full Text] [Related]
2. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
Li X; Gabriel DA
Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
[TBL] [Abstract][Full Text] [Related]
3. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
4. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.
Saenko E; Sarafanov A; Greco N; Shima M; Loster K; Schwinn H; Josic D
J Chromatogr A; 1999 Aug; 852(1):59-71. PubMed ID: 10480230
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
[TBL] [Abstract][Full Text] [Related]
6. A comparative in vitro evaluation of six von Willebrand factor concentrates.
Lethagen S; Carlson M; Hillarp A
Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
[TBL] [Abstract][Full Text] [Related]
7. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
[TBL] [Abstract][Full Text] [Related]
8. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.
Przeradzka MA; Meems H; van der Zwaan C; Ebberink EHTM; van den Biggelaar M; Mertens K; Meijer AB
Biochem J; 2018 Sep; 475(17):2819-2830. PubMed ID: 30111575
[TBL] [Abstract][Full Text] [Related]
9. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
[TBL] [Abstract][Full Text] [Related]
10. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
11. Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.
Kao KJ; Pizzo SV; McKee PA
J Clin Invest; 1979 Apr; 63(4):656-64. PubMed ID: 108291
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII and von Willebrand factor--too sweet for their own good.
Lenting PJ; Pegon JN; Christophe OD; Denis CV
Haemophilia; 2010 Jul; 16 Suppl 5():194-9. PubMed ID: 20590881
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expression.
Lavergne JM; Piao Y; Ribba AS; Girma JP; Siguret V; Piétu G; Boyer-Neumann C; Schandelong A; Bahnak BR; Meyer D
Thromb Haemost; 1993 Oct; 70(4):691-6. PubMed ID: 8115998
[TBL] [Abstract][Full Text] [Related]
14. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.
Cao W; Krishnaswamy S; Camire RM; Lenting PJ; Zheng XL
Proc Natl Acad Sci U S A; 2008 May; 105(21):7416-21. PubMed ID: 18492805
[TBL] [Abstract][Full Text] [Related]
16. von Willebrand factor protects the Ca2+-dependent structure of the factor VIII light chain.
Takeyama M; Nogami K; Okuda M; Shima M
Br J Haematol; 2009 Sep; 146(5):531-7. PubMed ID: 19594746
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.
Castro-Núñez L; Bloem E; Boon-Spijker MG; van der Zwaan C; van den Biggelaar M; Mertens K; Meijer AB
J Biol Chem; 2013 Jan; 288(1):393-400. PubMed ID: 23168412
[TBL] [Abstract][Full Text] [Related]
19. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII.
Saenko EL; Loster K; Josic D; Sarafanov AG
Thromb Res; 1999 Dec; 96(5):343-54. PubMed ID: 10605949
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
